Anavex Life Sciences Corp (AVXL)
3.44
+0.05
(+1.47%)
USD |
NASDAQ |
Apr 26, 16:00
3.435
0.00 (0.00%)
Pre-Market: 20:00
Anavex Life Sciences Free Cash Flow (Quarterly): -7.318M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.318M |
| September 30, 2023 | -5.850M |
| June 30, 2023 | -7.652M |
| March 31, 2023 | -8.489M |
| December 31, 2022 | -5.794M |
| September 30, 2022 | -4.044M |
| June 30, 2022 | -7.054M |
| March 31, 2022 | -9.640M |
| December 31, 2021 | -3.501M |
| September 30, 2021 | -7.675M |
| June 30, 2021 | -7.521M |
| March 31, 2021 | -7.317M |
| December 31, 2020 | -7.871M |
| September 30, 2020 | -6.255M |
| June 30, 2020 | -4.044M |
| March 31, 2020 | -5.263M |
| December 31, 2019 | -5.725M |
| September 30, 2019 | -2.534M |
| June 30, 2019 | -7.501M |
| March 31, 2019 | -4.332M |
| December 31, 2018 | -4.160M |
| September 30, 2018 | -4.053M |
| June 30, 2018 | -2.088M |
| March 31, 2018 | -2.821M |
| December 31, 2017 | -3.620M |
| Date | Value |
|---|---|
| September 30, 2017 | -2.192M |
| June 30, 2017 | -2.974M |
| March 31, 2017 | -0.6977M |
| December 31, 2016 | -3.154M |
| September 30, 2016 | -1.863M |
| June 30, 2016 | -2.224M |
| March 31, 2016 | -1.903M |
| December 31, 2015 | -3.247M |
| September 30, 2015 | -1.433M |
| June 30, 2015 | -1.430M |
| March 31, 2015 | -0.6703M |
| December 31, 2014 | -0.6931M |
| September 30, 2014 | -0.9175M |
| June 30, 2014 | -0.96M |
| March 31, 2014 | -0.3475M |
| December 31, 2013 | -0.4373M |
| September 30, 2013 | -0.4845M |
| June 30, 2013 | -0.0322M |
| March 31, 2013 | -0.1293M |
| December 31, 2012 | -0.1316M |
| September 30, 2012 | -0.2519M |
| June 30, 2012 | -0.2387M |
| March 31, 2012 | -0.1142M |
| December 31, 2011 | -1.088M |
| September 30, 2011 | -0.9226M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-9.640M
Minimum
Mar 2022
-2.534M
Maximum
Sep 2019
-6.371M
Average
-7.054M
Median
Jun 2022
Free Cash Flow (Quarterly) Benchmarks
| Ventyx Biosciences Inc | -51.87M |
| Checkpoint Therapeutics Inc | -6.833M |
| Vertex Pharmaceuticals Inc | 118.50M |
| Sarepta Therapeutics Inc | -73.70M |
| NovaBay Pharmaceuticals Inc | -0.316M |